التفاصيل البيبلوغرافية
| العنوان: |
Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. |
| المؤلفون: |
Dayimu, Alimu1 (AUTHOR), Di Lisio, Lorena2 (AUTHOR), Anand, Shubha2 (AUTHOR), Roca-Carreras, Isart2 (AUTHOR), Qian, Wendi3 (AUTHOR), Al-Mohammad, Abdulrahman4 (AUTHOR), Basu, Bristi5 (AUTHOR), Valle, Juan W.6 (AUTHOR), Jodrell, Duncan5 (AUTHOR), Demiris, Nikos3,7 (AUTHOR), Corrie, Pippa4 (AUTHOR) philippa.corrie@nhs.net |
| المصدر: |
British Journal of Cancer. May2023, Vol. 128 Issue 9, p1672-1680. 9p. |
| مستخلص: |
Background: Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) offers limited benefits, but survival outcomes vary. Reliable predictive response biomarkers to guide patient management are lacking. Methods: Patient performance status, tumour burden (determined by the presence or absence of liver metastases), plasma protein biomarkers (CA19-9, albumin, C-reactive protein and neutrophils) and circulating tumour DNA (ctDNA) were assessed in 146 patients with metastatic PDAC prior to starting either concomitant or sequential nab-paclitaxel + gemcitabine chemotherapy in the SIEGE randomised prospective clinical trial, as well as during the first 8 weeks of treatment. Correlations were made with objective response, death within 1 year and overall survival (OS). Results: Initial poor patient performance status, presence of liver metastases and detectable mutKRAS ctDNA all correlated with worse OS after adjusting for the different biomarkers of interest. Objective response at 8 weeks also correlated with OS (P = 0.026). Plasma biomarkers measured during treatment and prior to the first response assessment identified ≥10% decrease in albumin at 4 weeks predicted for worse OS (HR 4.75, 95% CI 1.43–16.94, P = 0.012), while any association of longitudinal evaluation of mutKRAS ctDNA with OS was unclear (β = 0.024, P = 0.057). Conclusions: Readily measurable patient variables can aid the prediction of outcomes from combination chemotherapy used to treat metastatic PDAC. The role of mutKRAS ctDNA as a tool to guide treatment warrants further exploration. Clinical trial registration: ISRCTN71070888; ClinialTrials.gov (NCT03529175). [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder